

SOCIETÀ ITALIANA DI FARMACOLOGIA

Convegno Monotematico GdL FARMACOLOGIA ONCOLOGICA


Evolution of cancer pharmacology

**Salerno
15-16 marzo
2024**



**"Grand Hotel Salerno"
Lungomare C. Tafuri, 1**

**Responsabile Scientifico
Prof.ssa Amelia Filippelli**



Scientific Committee

Mauro Biffoni	Giorgio Minotti
Giuseppe Cirino	Giuseppe Nocentini
Valeria Conti	Monica Notarbartolo di Villarosa
Bruno Daniele	Federica Papaccio
Amelia Filippelli	Marco Scatigna
Enrico Mini	Giuseppe Toffoli

Local Organizing Committee

Giuseppe Di Lorenzo	Antonello Petrella
Stefania Marzocco	Francesco Sabbatino
Silvana Morello	Rosalinda Sorrentino
Stefano Pepe	

Scientific Secretariat

Alessandra Bitto
Valeria Conti
Federica Papaccio

Contatti: monosif.oncologia@linkhealth.it

FACULTY

Biffoni Mauro (Roma)	Minotti Giorgio (Roma)
Bitto Alessandra (Messina)	Nocentini Giuseppe (Perugia)
Calon Alexandre (Barcellona - ES)	Notarbartolo di Villarosa Monica (Palermo)
Cirino Giuseppe (Napoli)	Papaccio Federica (Salerno)
Conti Valeria (Salerno)	Pepe Stefano (Salerno)
Daniele Bruno (Napoli)	Petrella Antonello (Salerno)
Di Lorenzo Giuseppe (Salerno)	Sava Gianni (Trieste)
Di Maio Massimo (Torino)	Scaccabarozzi Massimo (Milano)
Filippelli Amelia (Salerno)	Scatigna Marco (Milano)
Lombardi Pasquale (Roma)	Testoni Sara (Meldola, FC)
Malapelle Umberto (Napoli)	Toffoli Giuseppe (Aviano, PN)
Martinelli Erika (Napoli)	Workman Paul (Londra - UK)
Mini Enrico (Firenze)	



RATIONALE

In the last decades the therapeutic landscape of oncological diseases has been revolutionized by the introduction of targeted therapies and more recently immunotherapy. These significant clinical advances were possible thanks to the advances in basic and translational research. The aim of this congress is to provide an overview of the recent evolution of cancer pharmacology, from preclinical studies to clinical trial and regulatory issues.

GENERAL INFORMATION

The Conference will be held in Salerno March 15 – 16, 2024 at the conference centre of the “Grand Hotel Salerno”, Lungomare Clemente Tafuri, 1.

The event is aimed to 100 participants including Medical Doctors specialists in Pharmacology and Clinical Toxicology, Geriatrics, Oncology, Radiotherapy, General Practitioners, Pharmacists (public NHS, territorial and other sectors) and Biologists.

The event followed all the accreditation procedures at Age.Na.S. as part of the Continuing Medical Education project, obtaining 9 (nine) training credits.

In order to obtain the credits, it will be necessary to register for the conference, attend to all the scientific sessions and fill in the questionnaires provided at the end of the scientific work. The certification of credits will be sent by the Organizing Secretariat by e-mail to the address indicated on the personal data form within three months of the end of the conference.

A certificate of attendance will be issued to all registered participants at the end of the conference.

For any further information please contact the organizational secretariat on 089 255179 or by email at congressi@topcongress.it



Scan for abstract



SCIENTIFIC PROGRAM

Friday, 15th March 2024

13.15 Registration and welcome coffee

13.45 Opening and introduction

Amelia Filippelli, University of Salerno, Congress President

Vincenzo Loia, Rector of the University of Salerno

Carmine Vecchione, Pro-Rector of the University of Salerno

Annibale A. Puca, Head of the Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana"

Vincenzo D'Amato, General Director, University Hospital "San Giovanni di Dio e Ruggi d'Aragona" Salerno

Gennaro Sosto, General Director, ASL Salerno

Giovanni D'Angelo, President of Order of physicians and dentists

Giuseppe Cirino, SIF President

SESSION 1 – Preclinical models for drug development

14.00 Lecture: **Patient-derived models for drug development**

Alexandre Calon

Introduced by Federica Papaccio

14.25 Oral communications

Moderators: Monica Notarbartolo di Villarosa, Giuseppe Nocentini, Antonello Petrella

Peptide-platinum(IV) conjugation minimizes the negative effect of chemotherapy through low accumulation in the tumor microenvironment

Daniele Lo Re

Mitochondrial transfer via tunneling nanotubes from Adipose stem cells drives multi-drug resistance in breast cancer cells

Vitale Del Vecchio

Targeting Nrf2-regulated antioxidant systems to enhance chemotherapy response and ferroptosis induction in chemotolerant medulloblastoma cells

Roberta Bortolozzi

Differential enantiomeric activity of the RAD51-BRCA2 disruptor RS-35d for an intrinsic synthetic lethality strategy in pancreatic cancer

Mirco Masi

Improving doxorubicin delivery by using GQD in a -in vitro breast cancer model

Chiara Cullotta

Annexin A1 is involved in the antitumor effects of 5-azacytidine in human oral squamous carcinoma cells

Raffaella Belvedere



SESSION 2 – Emerging biomarkers for precision oncology: immunotherapeutics and Protein Kinase Inhibitors

15.40 Lecture: **The role of biomarkers in the therapeutic management of gastrointestinal and liver cancers**

Bruno Daniele

Introduced by Valeria Conti

16.05 Oral communications

Moderators: Giuseppe Toffoli, Erika Martinelli

Maintenance of anti-tumour innate immune response in SCLC with DNA-PK inhibition

Caterina De Rosa

Establishment of patient-derived tumor organoids to in vitro study ICIs sequential treatment in hepatocellular carcinoma

Luisa Amato

Immune-checkpoint inhibitors resistance in advanced non-small cell lung cancer: focus on platelets role

Chiara Colarusso

Enhancing cDC1-mediated antitumor response through disruption of aryl hydrocarbon receptor's tumor microenvironment sensing

Marco Gargaro

Nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer

Giuseppe Ercolano

CD73 induces an invasive and metastatic phenotype in melanoma under nutritional stress

Caterina Giraulo

17.20 Keynote Lecture: **Precision cancer therapeutics: design of chemical probes and drugs**

Paul Workman

Introduced by Enrico Mini

17.50 Closing remarks – Amelia Filippelli, Enrico Mini



Saturday, 16th March 2024

SESSION 3 – Real World and Early Treatment in Cancer Pharmacology

9.00 Lecture: **Real world studies in oncology**

Massimo Di Maio
Introduced by Amelia Filippelli

9.30 Oral communications

Moderators: Giorgio Minotti, Alessandra Bitto, Giuseppe Di Lorenzo

A machine learning approach to identify the best responder of carmustine wafer by germline variants

Maurizio Polano

Exploring PD-1 single nucleotide polymorphisms as predictive biomarkers for immune-related adverse events in advanced cancer patients treated with immunotherapy

Giovanna Polcaro

A personalized regorafenib dosing in recurrence glioblastoma according to an escalation dose scheme: preliminary results of a real world experience, the GLICINe trial

Pasqualina Giordano

Identification of adverse events related to drug-drug interactions in cancer patients receiving fluoropyrimidine-based treatment

Berenice Stefanelli

Polymorphisms in the TYMS gene as potential biomarkers of fluoropyrimidine-related toxicity

Emanuela De Bellis

Analysis of potential prognostic and/or predictive factors in a real-world population of advanced NSCLC patients treated with immune checkpoint inhibitors

Luigi Liguori

10.45 Lecture: **Science communication: the research in Cancer Pharmacology**

Gianni Sava
Introduced by Massimo Scaccabarozzi

11.05 Poster session

Chaired by the Local Organizing Committee and the Scientific Secretariat

ROUND TABLE: Challenges and pitfalls in biomarker studies implementation and in the access to innovative cancer drugs

Moderators: Stefano Pepe, Marco Scatigna



12.30 How to design a biomarker study

Pasquale Lombardi

12.45 Efficacy and effectiveness of biomarkers in clinical practice

Umberto Malapelle

13.00 Regulatory issues in biomarker studies: where are we now

Sara Testoni

13.15 Sustainability of innovative cancer drugs

Mauro Biffoni

13.30 Questions & Answers from the audience

14.00 SIF Award Ceremony – Best oral communication and Best poster, Working Group Cancer Pharmacology

SIF Award Ceremony – Equalia (edition 2023)

SIF Award Ceremony – in memory of Prof. Paolo Preziosi

SIF Award Ceremony – WG Pharmacognosy, Phytotherapy and Nutraceuticals (edition 2023)

The award presentation will be held by Giuseppe Cirino

14.30 Concluding Remarks



POSTER

- P1 Metabolomic profiling for non-invasive ovarian cancer screening**
Vera Abenante, Martina Lombardi, Nicole Palmieri, Alessio Trotta, Andrea Ingenito, Jacopo Troisi (Theoreo srl Salerno)
- P2 The nicotinamide phosphoribosyltransferase (NAMPT) as a novel therapeutic target for the treatment of glioblastoma multiforme (GBM)**
Nicole Abram, Cristina Lanni, Sergio Schinelli, Cristina Travelli, Mayra Paolillo (University of Pavia)
- P3 Targeting CIC chloride channels in human pancreatic ductal adenocarcinoma**
Concetta Altamura, Ilaria Saltarella, Carmen Campanale, Paola Laghetti, Giulia Maria Camerino, Daria Di Molfetta, Maria Raffaella Greco, Maria Antonia Frassanito, Rosa Angela Cardone, Jean-François Desaphy (University of Bari Aldo Moro)
- P4 Metformin sustains immune cells-mediated antitumor effects through cGAS/STING pathway in NSCLC patients**
Luisa Amato, Caterina De Rosa, Annalisa Ariano, Gaetano Di Guida, Isabella Vassallo, Concetta Tuccillo, Fortunato Ciardiello, Carminia Maria Della Corte, Floriana Morgillo (University of Campania Luigi Vanvitelli Naples)
- P5 Surface-modified nanoparticles for targeted siRNA delivery in colorectal cancer**
Rebecca Amico, Paola De Cicco, Giuseppe Longobardi, Claudia Conte, Fabiana Quaglia, Francesca Borrelli (University of Naples Federico II)
- P6 Nuclear protein 1 (nupr1) expression contributes to drug resistance in breast cancer cells**
Giuseppa Augello, Antonina Azzolina, Daniela Cabibi, Calogero Cipolla, Salvatore Vieni, Antonella Cusimano, Roberto Puleio, Juan Lucio Iovanna, Melchiorre Cervello (National Research Council Palermo)
- P7 eNAMPT increases breast cancer metastasis by modulating the epithelial-to-mesenchymal transition**
Federica Carolina Balestrero, Marianna Moro, Ambra Grolla (University of Eastern Piedmont Amedeo Avogadro Novara)
- P8 Antiproliferative effects of Sidnyum elegans extract in triple-negative breast cancer cells**
Martina Barile, Ivana Bello, Camilla Esposito, Marcello Casertano, Concetta Imperatore, Marialuisa Menna, Raffaella Sorrentino, Emma Mitidieri, Roberta d'Emmanuele di Villa Bianca, Elisabetta Panza (University of Naples Federico II)
- P9 Identification of novel selective HDAC6 inhibitor against triple negative breast cancer**
Ivana Bello, Simona Barone, Esposito Camilla, Martina Barile, Vincenzo Summa, Giuseppe Cirino, Margherita Brindisi, Elisabetta Panza (University of Naples Federico II)
- P10 Cytotoxic effects of targeted agents alone or combined with chemotherapy in the adenoid cystic carcinoma cells and in zebrafish model**
Sara Anna Bonini, Andrea Abate, Teresa Savarese, Ram Manohar Basnet, Luigi Lorini, Cristina Gurizzan, Michele Tomasoni, Davide Lombardi, Davide Mattavelli, Davide Tomasini, Daniela Zizioli, Maurizio Memo, Alfredo Berruti, Cesare Piazza, Paolo Bossi, Sandra Sigala (University of Brescia)
- P11 Modulating voltage-gated sodium channels and the ERK downstream to enhance differentiation and sensitize glioblastoma cells to chemotherapy**
Francesca Giammello, Chiara Biella, Erica Cecilia Piori, Matilde Amat Di San Filippo, Roberta Leone, Francesca D'Ambrosio, Martina Paternò, Giulia Cassioli, Cristina Spalletti, Ilaria Morella, Federica Barbieri, Giuseppe Lombardi, Tullio Florio, Riccardo Brambilla, Paola Rossi, Rossella Galli, Federico Brandalise (University of Milan)



- P12 Benzyl isothiocyanate promotes tumor suppression through modulation of autophagy in anaplastic thyroid carcinoma**
Giovanna Casili, Rossella Basilotta, Deborah Mannino, Alessia Filippone, Marika Lanza, Anna Paola Capra, Stefano Forte, Lorenzo Colarossi, Dorotea Sciacca, Salvatore Cuzzocrea, Emanuela Eposito, Irene Paterniti (University of Messina)
- P13 CAR-T gene therapies: multidisciplinary approach ed integrated**
Eliana Ciccone, Angelo Ferraro, Teresa D'Agostino (University of Salerno)
- P14 ALDH1A1 regulates stemness and resistance to RAF/MEK inhibitors in melanoma cells**
Valerio Ciccone, Vittoria Simonis, Arianna Filippelli, Lucia Morbidelli, Sandra Donnini (University of Siena)
- P15 Downregulation of TRPV3 correlates with tumor stemness and invasiveness in colon cancer**
 Donatella Cicia, Maria Miraglia, Fabio Cattaneo, Pietro Zoppoli, Maria Francesca Nani, Rebecca Amico, Ruggiero Lionetti, Giuseppe Merla, Barbara Romano, Raffaele Capasso, Angelo A. Izzo, Ester Pagano (University of Naples Federico II)
- P16 Exploring piperlongumine's potential: targeting cancer stem cells in pancreatic ductal adenocarcinoma for enhanced therapeutic efficacy**
Marianna Ciotola, Donatella delle Cave, Daniele Lo Re, Enza Lonardo (Institute of Genetics and Biophysics Adriano Buzzati-Traverso CNR Naples)
- P17 Gold nanoparticles (AuNPs) in the radio-sensitization of glioblastoma cells**
Laura Coppola, Cristina Pagano, Giovanna Navarra, Beatrice Savarese, Maria Moròs, Jesus Martinez de la Fuente, Alfredo Ambrosone, Caterina Oliviero, Roberto Pacelli, Chiara Laezza, Maurizio Bifulco (University of Naples Federico II)
- P18 Lipid-based nanoplatforms to deliver RNA-drugs in colorectal cancer**
Paola De Cicco, Rebecca Amico, Teresa Ferrillo, Claudia Conte, Fabiana Quaglia, Francesca Borrelli (University of Naples Federico II)
- P19 Antitumoral effect of Zosterabisphenone B, a new diarylheptanoid heterodimer isolated from the seagrass Zostera marina, in colon cancer**
Paola De Cicco, Nunzio Antonio Cacciola, Rebecca Amico, Maria Francesca Nani, Maria Miraglia, Laura Grauso, Silvia Scarpato, Alfonso Mangoni, Francesca Borrelli (University of Naples Federico II)
- P20 Adverse events associated with chemotherapy regimens containing fluoropyrimidine: findings from the multicentric italian study ONCO22**
Valeria Conti, Antonio Avallone, Sabrina Beltramini, Francesca Futura Bernardi, Elena Berti, Chiara Carlomagno, Giuseppina Della Vittoria Scarpato, Giuseppe Di Lorenzo, Elisena Franzese, Geppino Genua, Antonio Maria Grimaldi, Paola Marini, Vincenzo Montesarchio, Ugo Moretti, Stefano Pepe, Simona Peri, Laura Pesce, Barbara Rebesco, Ferdinando Riccardi, Raffaella Ruzza, Giuseppe Santabarbara, Antonia Silvestri, Giulia Sorrentino, Silvia Zuccarelli, Ugo Trama, Amelia Filippelli on behalf of ONCO22 collaborative group. AIFA-Funded Project - Regional Pharmacovigilance Funds 2012-2014 (University of Salerno)
- P21 Comparative analysis of severe toxicity risk in patients with dihydropyrimidine dehydrogenase genetic variations undergoing fluoropyrimidine-based chemotherapy: insights from the ONCO22 study**
Valeria Conti, Antonio Avallone, Sabrina Beltramini, Francesca Futura Bernardi, Elena Berti, Chiara Carlomagno, Giuseppina Della Vittoria Scarpato, Giuseppe Di Lorenzo, Elisena Franzese, Geppino Genua, Antonio Maria Grimaldi, Paola Marini, Vincenzo Montesarchio, Ugo Moretti, Stefano Pepe, Simona Peri, Laura Pesce, Barbara Rebesco, Ferdinando Riccardi, Raffaella Ruzza, Giuseppe Santabarbara, Antonia Silvestri, Giulia Sorrentino, Silvia Zuccarelli, Ugo Trama, Amelia Filippelli on behalf of ONCO22 collaborative group. AIFA-Funded Project - Regional Pharmacovigilance Funds 2012-2014 (University of Salerno)



- P22 Evaluating the effect of lenvatinib–resistance in hepatocellular carcinoma cells**
Luisa Amato, Caterina De Rosa, Annalisa Ariano, Concetta Tuccillo, Vincenza Ciaramella, Fortunato Ciardiello, Giulia Martini, Erika Martinelli (University of Campania Luigi Vanvitelli Naples)
- P23 Targeting collagen in PDAC reduces aggressiveness by enhancing LICAM expression**
Donatella Delle Cave, Marco Fantuz, Alessandro Carrer, Annalisa Di Domenico, Enza Lonardo (Institute of Genetics and Biophysics Adriano Buzzati-Traverso CNR Naples)
- P24 Sepsis risk stratification in newly diagnosed multiple myeloma patients receiving anti-CD38 target therapy**
Vanessa Desantis, Paola Borrelli, Lucia Di Marzo, Antonietta Scaringella, Teresa Panebianco, Antonio Fusillo, Donatello Bochicchio, Fabrizio Pappagallo, Antonella Mascolo, Alessandro Andriano, Ingrid Catalina Caradonna, Angelo Vacca, Antonio Giovanni Solimando, Monica Montagnani (University of Bari Aldo Moro)
- P25 Role of microRNAs in predicting therapeutic response of gastrointestinal cancer patients treated with fluoropyrimidines**
Daniilo Donnarumma, Emanuela De Bellis, Ines Mazza, Berenice Stefanelli, Federica De Rosa, Adele Zarrella, Federica Papaccio, Valeria Conti, Amelia Filippelli (University of Salerno)
- P26 Erucin, an H2S–releasing isothiocyanate, exert anticancer effect on human triple negative breast cancer cells**
Camilla Esposito, Ivana Bello, Martina Smimmo, Maria Rosaria Bucci, Giuseppe Cirino, Elisabetta Panza (University of Naples Federico II)
- P27 IL41l in the tumor microenvironment: unraveling its impact on immune responses and tumor dynamics**
Marco Gargaro, Giulia Mencarelli, Andrea Marra, Estevão Carlos Silva Barcelos, Andrea Astolfi, Giorgia Manni, Giulia Scalisi, Dorianna Ricciuti, Benedetta Pieroni, Francesco Sarnari, Alessandro Pinzi, Giuseppe Manfroni, Marco Colonna, Maria Letizia Barreca, Peter J. Murray, Kenneth M. Murphy, Francesca Fallarino (University of Perugia)
- P28 Tumours caused by obesity: the key role of adiponectin**
Francesco Ferrara, Maurizio Capuozzo, Roberto Langella, Ugo Trama, Andrea Zovi (Local Health Authority Naples 3 South)
- P29 Dissecting the microenvironment of malignant gliomas using intraoperative dyes as a tumor–specific biomarker of infiltration. A focus on infiltrating macrophages polarization status**
Chiara Ferraro, Giuseppe Maria della Pepa, Gabriella Maria Pia Ciotti, Alessandro Olivi, Pierluigi Navarra, Lucia Lisi (University Hospital Agostino Gemelli Catholic University of the Sacred Heart Rome)
- P30 Casein kinase 2 inhibitor, CX–4945, induces apoptosis and re–store blood brain barrier homeostasis altered in glioblastoma**
Alessia Filippone, Irene Paterniti, Giovanna Casili, Valentina Bova, Deborah Mannino, Emanuela Esposito (University of Messina)
- P31 Development and characterization of breast cancer organoids as a platform for boosting the preclinical development of novel pharmacological approaches**
Federica Foglietta, Marta Giaccone, Roberto Canaparo, Giuseppa Augello, Antonella Cusimano, Roberto Puleio, Vincenza Cannella, Lucia Condorelli, Giulio Giannone, Daniela Cabibi, Calogero Cipolla, Salvatore Vieni, Melchiorre Cervello, Loredana Serpe (University of Torino)
- P32 Reversing doxorubicin resistance in osteosarcoma cell lines through pharmacological modulation of mitochondrial alterations**
Isabella Giacomini, Veronica Cocetta, Mattia Tinazzi, Margherita Cortini, Sofia Avnet, Nicola Baldini, Eugenio Ragazzi, Monica Montopoli (University of Padua)



P33 Nicotinamide Phosphoribosyltransferase (NAMPT) sustains cancer through its different moonlighting functions

Marianna Moro, Federica Carolina Balestrero, [Ambra Grolla](#)
(University of Eastern Piedmont Amedeo Avogadro Novara)

P34 A Metabolomic approach enhanced by machine learning for colorectal cancer screening

[Andrea Ingenito](#), Martina Lombardi, Nicole Palmieri, Alessio Trotta, Vera Abenante, Jacopo Troisi (Theoreo srl Salerno)

P35 Antitumor effects of bortezomib linked to graphene quantum dots in an in vitro model of hepatocellular carcinoma

[Rita Lauro](#), Chiara Imbesi, Chiara Cullotta, Alessandra Bitto (University of Messina)

P36 Insights into RACK1 regulation and its related inflammation and tumor microenvironment (TME) in triple-negative breast cancer (TNBC): towards personalized therapy

[Roberta Valeria Limosani](#), Chiara Oliviero, André Fiou, Mirco Masi, Marco Bolis, Luca Guarrera, Enrico Garattini, Marco Racchi, Erica Buoso (University of Pavia)

P37 The orphan nuclear receptor NR2F6 a novel regulator of cancer immune responses

[Giorgia Manni](#), Doriana Ricciuti, Francesco Antonio Greco, Daniela Passeri, Francesca De Franco, Marco Gargaro, Francesco Sarnari, Giulia Mencarelli, Benedetta Pieroni, Alessandro Pinzi, Roberto Pellicciari, Francesca Fallarino (University of Perugia)

P38 Pro-tumoral role of type-2 Innate lymphoid cells (ILC2s) in prostate cancer patients

[Daniela Claudia Maresca](#), Evelina La Civita, Barbara Romano, Monica Ambrosio, Fabio Somma, Angela Iannaro, Daniela Terracciano, Giuseppe Ercolano (University of Naples Federico II)

P39 Expert survey on the management of metastatic colorectal cancer in the Campania region: real-world insights into clinical approaches

[Giulia Martini](#), Antonio Avallone, Simona Cammarota, Chiara Carlomagno, Anna Citarella, Ilaria Di Giovanni, Antonietta Fabbrocini, Pietro Fimiani, Antonio Grimaldi, Pasquale Incoronato, Luigi Leo, Erika Martinelli, Vincenzo Montesarchio, Michele Oritura, Stefano Pepe, Ferdinando Riccardi, Giuseppe Santabarbara, Fortunato Ciardiello, Stefania Napolitano (University of Campania Luigi Vanvitelli Naples)

P40 Safety profiles of the new target therapies pemigatinib, futibatnib and ivosidenib for the treatment of cholangiocarcinoma: a systematic review of the literature

[Giulia Matranga](#), Anna Carollo, Sofia Cutaia, Miriam Alaimo, Alessio Provenzani, Sergio Rizzo (University Hospital Agostino Gemelli Catholic University of the Sacred Heart Rome)

P41 Impact of pharmacovigilance in oncology

[Salvatore Maria Mazzeo](#), Danilo Donnarumma, Adele Zarrella, Berenice Stefanelli, Rossella Centola, Maria Alfieri, Stefania Caruso, Roberta Benedetto, Dario Arundine, Clementina Savastano, Stefano Pepe, Valeria Conti, Amelia Filippelli (University of Salerno)

P42 TRPV3 is a key regulator of functional and metabolic activities of pro-tumoral macrophages

[Maria Miraglia](#), Donatella Cicia, Paola De Cicco, Pietro Zoppoli, Maria Francesca Nani, Giuseppe Merla, Barbara Romano, Francesca Borrelli, Angelo A. Izzo, Ester Pagano (University of Naples Federico II)

P43 Cigarette smoke exposure promotes tumorigenesis via G-quadruplex destabilization in a vitro model of macrophages

[Davida Mirra](#), Giuseppe Spaziano, Renata Esposito, Francesca Panico, Salvatore Di Maro, Erica Salvati, Erika Cione, Luca Gallelli, Sandro Cosconati, Bruno D'Agostino (University of Campania Luigi Vanvitelli Naples)



- P44 Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) as a novel driver in breast cancer angiogenesis**
Marianna Moro, Federica Carolina Balestrero, Sabina Sangaletti, Sandra Donnini, Armando A. Genazzani, Ambra A. Grolla (University of Eastern Piedmont Amedeo Avogadro Novara)
- P45 S-adenosylmethionine inhibits cancer cell growth through upregulating the tumor suppressor miR-34a**
Laura Mosca, Francesca Cadoni, Roberta Arpino, Roberta Grillo, Roberta Veglia Tranchese, Giovanna Cacciapuoti, Marina Porcelli (University of Campania Luigi Vanvitelli Naples)
- P46 NAPE-PLD pharmacological modulation influences obesity linked to colon cancer**
Maria Francesca Nani, Paola De Cicco, Maria Miraglia, Ester Pagano, Fabiana Piscitelli, Stefano Tomassi, Rebecca Amico, Francesca Borrelli, Luciana Marinelli, Angelo A. Izzo, Barbara Romano (University of Naples Federico II)
- P47 Validation of single nucleotide polymorphisms predictive of R-CHOP response in diffuse large B-cell lymphoma patients**
Stefania Nobili, Gabriele Perrone, Luigi Rigacci, Giandomenico Roviello, Ida Landini, Alberto Fabbri, Lorenzo Iovino, Benedetta Puccini, Emanuele Cencini, Enrico Orciuolo, Alberto Bosi, Monica Bocchia, Enrico Mini (University of Florence)
- P48 N6-isopentenyladenosine impairs mitochondrial metabolism through inhibition of EGFR translocation on mitochondria in glioblastoma cells**
Cristina Pagano, Laura Coppola, Giovanna Navarra, Giorgio Avilia, Sara Bruzzaniti, Erica Piemonte, Mario Galgani, Rosa Della Monica, Lorenzo Chiarriotti, Mariella Cuomo, Michela Buonaiuto, Giovanni Torelli, Pasquale Caiazzo, Chiara Laezza, Maurizio Bifulco (University of Naples Federico II)
- P49 Advancing male uro-genital cancer screening with metabolomic profiling and ensemble machine learning**
Nicole Palmieri, Martina Lombardi, Andrea Ingenito, Alessio Trotta, Vera Abenante, Jacopo Troisi (Theoreo srl Salerno)
- P50 Nivolumab and chemotherapy as first-line therapy in metastatic HER-2 negative gastric cancer: real-world data from a single institution experience**
 Eleonora Mirra, Francesco Bove, Piera Federico, Antonietta Fabbrocini, Raimondo Di Liello, Pasqualina Giordano, Bruno Daniele, Angelica Petrillo (Ospedale del Mare Naples)
- P51 The antitumoral activity of carnosine in SH-SY5Y neuroblastoma cells is mediated by the expression of TNF- α and TGF- β 1**
Anna Privitera, Lucia Di Pietro, Loredana Leggio, Fabrizio Cavallaro, Marco Catania, Marco Falcone, Filippo Caraci, Nunzio Iraci, Giuseppe Caruso (University of Catania)
- P52 Antimigratory effects of SEMBL in 2D and 3D breast cancer models**
Salvatrice Rigogliuso, Alessandra Cusimano, Manuela Labbozzetta, Francesco Carfi Pavia, Carbone Camilla, Paola Poma, Monica Notarbartolo (University of Palermo)
- P53 NO-releasing doxorubicin molecule reverses doxorubicin resistance in human lung carcinoma cells**
Benedetta Romano, Daniela Claudia Maresca, Fabio Somma, Mariacristina Failla, Federica Sodano and Giuseppe Ercolano, Angela Ianaro (University of Naples Federico II)
- P54 The SIRT2/p53 axis underlying the anti-proliferative effect of bergamot juice extract and its flavanones in leukaemia THP-1 cell line**
Caterina Russo, Alessandro Maugeri, Laura Musumeci, Navarra Michele (University of Messina)



P55 Bispecific DARPIn molecules in multiple myeloma settings

Ilaria Saltarella, Aurelia Lamanuzzi, Assunta Melaccio, Concetta Altamura, Alexander Link, Joanna Robinson, Christian Reichen, Roberto Ria, Angelo Vacca, Maria Antonia Frassanito, Jean-François Desaphy (University of Bari Aldo Moro)

P56 Pharmaconutrition in cancer

Carmine Sellitto, Berenice Stefanelli, Federico Rea, Vincenzo D'Amato, Catia De Sio, Walter Longanella, Emilia Anna Vozzella, Valeria Conti, Amelia Filippelli (University of Salerno)

P57 Ircinia ramosa SPONGE EXTRACT (ISP) induces apoptosis in human melanoma cells and inhibits melanoma cell migration and invasiveness

Fabio Somma, Benedetta Romano, Daniela Claudia Maresca, Giuseppina Chianese, Carmen Formisano, Angela Ianaro, Giuseppe Ercolano (University of Naples Federico II)

P58 Safety of pembrolizumab in esophageal cancer (EAC): an analysis of EudraVigilance database

Desirée Speranza, Enrica Maiorana, Maricarmela Cavaleri, Fausto Omero, Paola Maria Cutroneo, Vincenzo Cianci, Mariacarmela Santaripa, Tindara Franchina, Edoardo Spina, Nicola Silvestris (University of Messina)

P59 Zebrafish embryos xenografted with adrenocortical carcinoma cells represent an useful experimental tool to test antitumoral drug activity

Mariangela Tamburello, Andrea Abate, Elisa Rossini, Daniela Zizioli, Ram Manohar Basnet, Giovanni Ribauda, Alessandra Gianoncelli, Guido A.M. Tiberio, Enzo Lalli, Carmen Ruggiero, Constanze Hantel, Alfredo Berruti, Sandra Sigala (University of Brescia)

P60 The WEE1 kinase inhibitor adavosertib - a promising therapeutic enhancer of cytotoxic therapies in advanced adrenocortical carcinoma

Mariangela Tamburello, Silviu Sbiera, Tessa Holmstoen, Marc P. Schauer, Justus Weber, Stefan Kircher, Laura-Sophie Landwehr, Otilia Kimpel, Juliane Lippert, Mario Detomas, Hanna Urlaub, Sonja Steinhauer, Margaret E. Wierman, Constanze Hantel, Sandra Sigala, Cristina L. Ronchi, Michael Hudecek, Katja Kiseljak-Vassiliades, Martin Fassnacht, Barbara Altieri (University of Würzburg)

P61 Simvastatin enhances the cytotoxic effects of doxorubicin in a mammary adenocarcinoma cell model: involvement of connexin 43

Roberta Vitale, Stefania Marzocco, Ada Popolo (University of Salerno)

P62 Exploring new PPI-inhibitors: pharmacological and functional characterization targeting eph-ephrin interaction in glioblastoma

Alfonso Zappia, Francesca Romana Ferrari, Elisabetta Barocelli, Vigilio Ballabeni, Simona Bertoni, Riccardo Castelli, Lorenzo Guidetti, Alessio Lodola, Carmine Giorgio, Melanie P. Clements, Anni Poysti, Simona Parrinello, Massimiliano Tognolini (University of Parma)


P63 Circulating tumor cells: prognostic and predictive biomarkers in precision oncology

Andrea Zovi, Maurizio Capuozzo, Roberto Langella, Ugo Trama, Francesco Ferrara (Ministry of Health)





Scan for abstract



CON IL PATROCINIO DI:



Dipartimento di Medicina e Chirurgia
Università degli Studi di Salerno



A.O.U. San Giovanni di Dio
e Ruggi d'Aragona



FNOMCeO

Federazione Nazionale degli Ordini
dei Medici Chirurghi e degli Odontoiatri



**ordine dei medici
e degli odontoiatri
della provincia di Salerno**



FARMINDUSTRIA



**CONFINDUSTRIA
Dispositivi Medici**



SIF
SOCIETÀ ITALIANA DI FARMACOLOGIA



ASSOCIAZIONE
ITALIANA
ONCOLOGIA
MEDICA

CON IL CONTRIBUTO NON CONDIZIONANTE DI:



Provider Nazionale ID 2085
Via Danilo Stjepovich, 13 - 00121 Roma
Tel. 0664670107 • Mobile 3475905830
info@beacongressi.it



Via Settimio Mobilio, 174 - 84127 Salerno
Tel. 089 255179 - Fax 089 9307025
e-mail: congressi@topcongress.it
www.topcongress.it